Results 11 to 20 of about 64,978 (265)
Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma [PDF]
Discover OncologyBackground The combination of rituximab and chemotherapy is a first-line treatment for patients with B-cell non-Hodgkin lymphoma. Lenalidomide is an immunomodulatory drug that has shown promising properties and activity in a variety of hematological ...
Yang Liu +13 more
doaj +2 more sources
The molecular pathogenesis of B‐cell non‐Hodgkin lymphoma [PDF]
European Journal of Haematology, 2015 AbstractThe B‐cell non‐Hodgkin lymphomas (B‐NHL) are a diverse group of haematological malignancies which arise from the mature B‐lymphocyte compartment. Recently, our understanding of the molecular pathogenesis of these disorders has greatly increased due to technological advances such as high‐throughput DNA sequencing techniques.
Piers A, Blombery +2 more
openaire +2 more sources
Radioimmunotherapy for B-Cell Non-Hodgkin Lymphomas [PDF]
Cancer Control, 2012 Radioimmunotherapy (RIT) is a safe and effective therapeutic option for patients with indolent B-cell non-Hodgkin lymphomas (NHL), in both up-front and relapsed/refractory settings. Two approved agents (90Y-ibritumomab tiuxetan and 131I-tositumomab) are available in the United States.
openaire +2 more sources
Association of group erythrocyte antigens and B-cell non-Hodgkin lymphoma
Regulatory Mechanisms in Biosystems, 2016 We analyzed the frequency distribution of blood groups AB0, Rhesus and Kell in patients with B-cell non-Hodgkin lymphoma. An increase of D− patients (31.0%) among ill in comparison to healthy individuals (16.5%) was found.
U. V. Tymoshenko +4 more
doaj +1 more source
Urology Annals, 2015 Large B-cell non-Hodgkin lymphoma involving the prostate accounts for 0.09% and 0.1% of non-Hodgkin lymphoma. We report a case of prostatic large B-cell non-Hodgkin lymphoma in a 77-year-old male with symptoms of urinary retention most probably due to ...
Ram Nawal Rao +4 more
doaj +1 more source
Central Asian Journal of Medical Sciences, 2020 Objectives: This study was conducted to determine the effect of Hepatitis B infection with or without D coinfection on the hepatitis flare associated with chemotherapy for B-Cell non-Hodgkin lymphoma.
Myagmarjav Budeebazar +8 more
doaj +1 more source
Diverse hematological malignancies including hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice. [PDF]
PLoS ONE, 2009 A chimeric HLA-DR4-H2-E (DR4) homozygous transgenic mouse line spontaneously develops diverse hematological malignancies with high frequency (70%).
Silke H Raffegerst +5 more
doaj +1 more source
EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda
Infectious Agents and Cancer, 2010 Background B cell non Hodgkin lymphomas account for the majority of lymphomas in Uganda. The commonest is endemic Burkitt lymphoma, followed by diffuse large-B-cell lymphoma (DLBCL). There has been an increase in incidence of malignant lymphoma since the
Pileri Stefano A +4 more
doaj +1 more source
Investigating a fast-growing nodule on the face: A case of primary cutaneous marginal zone lymphoma [PDF]
Journal of Krishna Institute of Medical Sciences University, 2022 Primary cutaneous B-cell lymphomas are non-Hodgkin lymphomas that present in the skin without evidence of extracutaneous involvement at diagnosis. There are three types of primary cutaneous B-cell lymphomas: primary cutaneous marginal zone lymphoma ...
N. Ashok Kumar +3 more
doaj
Breakthrough therapies in B-cell non-Hodgkin lymphoma
Annals of Oncology, 2016 The last 5 years have seen significant advances in our understanding of the molecular pathogenesis of B-cell lymphomas. This has led to the emergence of a large number of new therapeutic agents exploiting precise aspects of the tumor cell's signaling pathways, surface antigens or microenvironment.
C Y, Cheah, N H, Fowler, M L, Wang
openaire +2 more sources